Pulmonology

Alnylam has announced this afternoon that the U.S. FDA has accepted for filing its New Drug Application for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of hATTR amyloidosis.

The CDC attributes up to 21% of US asthma deaths to occupational exposures, and considers many potentially avoidable.

Results from a study recently published in the Orphanet Journal of Rare Diseases confirms the idea that tuberous sclerosis complex (TSC) can be diagnosed before seizure onset.

The first patient was enrolled in Mallinckrodt’s Phase 4 pilot study to further assess the efficacy of H.P. Acthar Gel (Repository Corticotropin Injection) in patients with pulmonary sarcoidosis.

This morning, Aradigm announced that it received a Complete Response Letter, denying its New Drug Application for Linhaliq.

Alnylam announced that its Marketing Authorisation Application for patisiran was accepted by the European Medicines Agency.

Faron Pharmaceuticals announced this morning that the U.S. FDA has approved the Investigational New Drug application for Traumakine (FP-1201-lyo) for the treatment of Acute Respiratory Distress Syndrome.

Children whose mothers had a higher intake of sugar sweetened beverages and total fructose had a 19% greater chance of developing asthma in mid-childhood.

Two doses of dexamethasone resulted in similar outcomes with better adherence than five days of prednisone in children with acute asthma.

Today, Eiger BioPharmaceuticals announced that results from the Phase 2 LIBERTY study demonstrated no improvement overall in its Phase 2 PAH treatment study, evaluating the effects of ubenimex.

A 1 mcg/m3 increase in average fine PM was associated 7.2% increase in asthma hospitalizations for patients aged 5 to 20 years old.

Boehringer Ingelheim announced the approval of a new indication for afatinib, as the U.S. FDA approved a supplemental NDA for the first-line treatment of patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations.

The Antimicrobial Drugs Advisory Committee voted 12-3 against supporting whether Aradigm Corporation provided substantial evidence for the safety and efficacy of inhaled ciprofloxacin dispersion.

From January 2012 to July 2017, the FDA reportedly received 79 Medical Device Reports (MDRs) pertaining to pneumothorax events, including 16 deaths.

A new study looked at thousands of asthma patients in order to better understand the genetic associations of asthma.

The FDA recently approved the therapy after showing reduction in patients' polyp grade, and reduction in sense of nasal obstruction and congestion.

The trial featured schoolchildren with persistent asthma from an urban region.

The discovery fills a gap in lacking non-drug asthma therapies which health care providers can recommend to patients.

New research shows overweight preschoolers have more frequent asthma symptoms, but inhalers are still effective.

Researchers included smaller city, town, and rural residents for the study, noting they were populations previously excluded from US pollution-based studies.

Breastfeeding is associated with lower odds of developing asthma compared to formula than bottle feeding with expressed breast milk.

The label removal was backed by 4 clinical safety trials involving more than 40,000 patients.

A Lenox Hill Hospital dermatologist outlines the threats surrounding, and ideal therapies for, dermatological conditions brought on by pollution.

The first once-daily, triple-therapy inhaler drug was originally approved by the FDA in September.